Medical diagnostics company Visby Medical raised $100 million in a Series E round earlier this year. Today, the company told me it extended that round by an additional $35 million at the same valuation as the rest of the round. This financing will enable Visby Medical to scale production capacity from tens to hundreds of thousands of monthly tests. It will also further expand its product lineup to include COVID + influenza A/B combination testing, antimicrobial resistance panels, and deliver at-home PCR diagnostics to consumers.
“The valuation is just over $1B post-money,” a spokesperson for the company told TechCrunch over email. “The extension is at the same valuation as the rest of the round, which we think demonstrates that these are long-term investors, not i …
